Waiting for Senate to Act on Track and Trace Bill

A track and trace bill is still awaiting a hearing in the Senate, where there are supporters from both sides of the aisle.

The bill won approval from the House of Representatives on Sept. 25.

The bill would require pharmaceutical companies to create a database to track their products. The database would enable pharmaceutical companies to comply with the legislation, which gives companies 24 hours to answer questions about a drug’s authenticity.

If the current bill is signed into law by President Obama, pharmaceutical companies will have a 10-year deadline to completely adopt new track and trace regulations.

Federal track and trace requirements would supersede state regulations, such as California’s E-Pedigree law.

USDM is already helping many of the world's most well-known medical device companies prepare for the pending legislation.